WallStSmart

Medtronic PLC (MDT)vsNuwellis Inc (NUWE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 416432% more annual revenue ($37.54B vs $9.01M). MDT leads profitability with a 13.9% profit margin vs -125.6%. MDT earns a higher WallStSmart Score of 68/100 (B-).

MDT

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99

NUWE

Avoid

35

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 6.7Quality: 5.5
Piotroski: 2/9Altman Z: -73.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDTUndervalued (+3.7%)

Margin of Safety

+3.7%

Fair Value

$94.43

Current Price

$90.96

$3.47 discount

UndervaluedFair: $94.43Overvalued
NUWEUndervalued (+90.0%)

Margin of Safety

+90.0%

Fair Value

$22.04

Current Price

$0.77

$21.27 discount

UndervaluedFair: $22.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$116.35B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

EPS GrowthGrowth
40.7%8/10

Earnings expanding 40.7% YoY

Free Cash FlowQuality
$1.29B8/10

Generating 1.3B in free cash flow

NUWE1 strengths · Avg: 10.0/10
Debt/EquityHealth
-0.1010/10

Conservative balance sheet, low leverage

Areas to Watch

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.654/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

NUWE4 concerns · Avg: 2.5/10
Market CapQuality
$2.48M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-657.5%2/10

ROE of -657.5% — below average capital efficiency

EPS GrowthGrowth
-99.2%2/10

Earnings declined 99.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.

Bull Case : NUWE

The strongest argument for NUWE centers on Debt/Equity. Revenue growth of 14.1% demonstrates continued momentum.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Bear Case : NUWE

The primary concerns for NUWE are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

MDT profiles as a value stock while NUWE is a turnaround play — different risk/reward profiles.

MDT carries more volatility with a beta of 0.57 — expect wider price swings.

NUWE is growing revenue faster at 14.1% — sustainability is the question.

MDT generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (68/100 vs 35/100) and 13.7% revenue growth. NUWE offers better value entry with a 90.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Nuwellis Inc

HEALTHCARE · MEDICAL DEVICES · USA

Nuwellis, Inc., a medical device company, focuses on the development, manufacture and marketing of medical devices used in ultrafiltration therapy. The company is headquartered in Eden Prairie, Minnesota.

Want to dig deeper into these stocks?